H.B. Fuller Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FUL research report →
Range $55 – $67
Price Chart
About the company
H. B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives, and other specialty chemical products.
- CEO
- Celeste Mastin
- IPO
- 1973
- Employees
- 7,100
- HQ
- Saint Paul, MN, US
AI snapshot
Six angles, distilled from the data.
The stock is in a long corrective regime, trading well below its 200-day average of 57.76 and still far under the 52-week high of 67.72. It has stabilized closer to the lower end of its yearly range, with the 50-day average also below the 200-day line, signaling a still-muted intermediate trend.
Street sentiment stays constructive, with a Buy consensus and an average target of 62.33 versus a recent close near 49.47. Recent calls have been more cautious on valuation, with several target cuts in 2026, but the rating mix still leans positive at 9 Buys and 6 Holds.
Execution has been steady: H.B. Fuller has beaten EPS in 7 of the last 8 quarters, including a 4.8% beat in the latest report. Next-year EPS estimates rise to 5.15 from a 2026 average of 4.85, so shareholders should watch whether margin discipline keeps pace with that step-up.
The pattern is modestly constructive, led by discretionary buying from a director and an officer, while the lone sale was smaller than the purchases. Most other filings are award, vesting, or exempt-share mechanics, which are routine compensation noise rather than a clear sentiment signal.
Profitability is solid for the group, with a 32.7% gross margin, 12% operating margin, and 5.56% net margin. Growth is improving too, with revenue up 5.2% year over year and earnings up 18%, while free cash flow reached $405.8 million and covered a 15.29% yield.
H.B. Fuller sits in the specialty chemicals lane with a steadier beta profile than many industrial peers, but the market still values it below its own historical range. At 10.9x earnings, the setup looks cheaper than the broader quality-growth tape, though leverage remains a watch item.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.49B
- P/E
- 12.76
- Fwd P/E
- 9.53
- PEG
- 0.01
- P/S
- 0.70
- P/B
- 1.16
- EV/EBITDA
- 8.24
- Div Yield
- 2.09%
- Gross Margin
- 32.79%
- Op Margin
- 11.53%
- Net Margin
- 5.56%
- ROE
- 9.51%
- ROIC
- 6.57%
Latest fiscal year · YoY change
- Revenue
- $3.47B-2.7%
- Gross Profit
- $1.10B+2.5%
- Op Income
- $399.12M
- Net Income
- $151.97M+16.7%
- EPS
- $2.78+17.3%
- OCF Growth
- -12.9%
- FCF Growth
- -25.7%
- 52W High
- $68.63
- 52W Low
- $46.11
- 50D MA
- $50.13
- 200D MA
- $57.47
- Beta
- 0.97
- RSI (14)
- 38
- Avg Volume
- 724.66K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
H.B. Fuller delivered solid Q3 growth with margin expansion on pricing and restructuring, while reaffirming 2026 guidance and reiterating confidence in Quantum Leap and the pending AMS acquisition.· September 24, 2026
- Q3 revenue rose 5.2% year over year; organic revenue was up 4.4% on 7.4% pricing, partially offset by lower volume.
- Adjusted EBITDA increased 9% to $187 million and adjusted EPS rose 21% to $1.52; adjusted gross margin expanded 120 bps to 33.5%.
- Management said pricing is still offsetting elevated raw material costs, and Q3 margin strength reflected pricing execution plus restructuring savings.
- Full-year 2026 guidance was maintained to slightly tightened: adjusted EBITDA of $655 million-$670 million and adjusted EPS of $4.70-$4.85.
- The company said AMS remains on track to close by year-end, while Quantum Leap is expected to drive further savings and cash flow gains into 2027.
Third-quarter revenue increased 5.2% year over year, with organic revenue up 4.4% after a 0.8% positive contribution from currency and acquisitions. Adjusted gross profit margin was 33.5%, up 120 basis points, adjusted EBITDA was $187 million, up 9%, and adjusted EPS was $1.52, up 21%. Net working capital was 18.5% of annualized net revenue, up 150 basis points year over year, and year-to-date cash flow from operations was $183 million, up 17%. For fiscal 2026, management expects net revenue to be up mid-single digits, organic revenue up low single digits, adjusted EBITDA of $655 million to $670 million, adjusted EPS of $4.70 to $4.85, and cash flow from operations of $300 million to $325 million excluding AMS-related items.
Celeste Mastin framed the quarter as evidence that the company’s strategy is working, emphasizing disciplined execution, pricing discipline, and restructuring. She said H.B. Fuller is making progress toward its EBITDA margin target of greater than 20% and highlighted confidence in Quantum Leap as a long-term earnings and cash flow driver. She also said the company remains confident in the strategic merits of AMS and in its ability to strengthen the portfolio while pursuing long-term value creation.
John Corkrean said pricing and restructuring savings more than offset lower volume in the quarter, driving adjusted gross margin to 33.5% and EBITDA to $187 million. He noted net working capital was 18.5% of annualized net revenue, year-to-date operating cash flow was $183 million, and leverage was slightly less than 3x net debt to adjusted EBITDA versus 3.3x a year ago. On guidance, he reiterated 2026 adjusted EBITDA of $655 million-$670 million, adjusted EPS of $4.70-$4.85, and operating cash flow of $300 million-$325 million excluding AMS. He also said Quantum Leap should deliver about $20 million to $25 million of incremental savings in 2027, with leverage and capital spending expected to improve over time.
Analysts focused on why volume held up better than expected, whether volumes can turn positive in 2027, and how to think about margin expansion and pricing into next year. Management said Q3 volumes were better because customers did not face the material shortages they had expected, while demand patterns were choppy and harder to forecast. On 2027, they pointed to easier solar comps, potential stabilization in electronics and construction, continued pricing actions, and Quantum Leap savings, while flagging China and construction as key areas to watch.
The call showed pricing power still working, with 7.4% organic pricing in the quarter and exit pricing at 7.6%, while margins expanded despite lower volume. Management sounded increasingly confident that Quantum Leap, portfolio actions, and AMS will support further EBITDA, cash flow, and strategic growth. They also pointed to share gains and innovation in several businesses, including BAS and Asia-Pacific HHC.
Volume remains choppy, with lower volume still offsetting pricing and management pointing to electronics, construction, China, and large CPG demand as ongoing pressure points. Raw material costs remain elevated, and management said next year’s pricing/raw spread will be positive but less favorable than this year. The AMS deal also adds financing and deleveraging execution risk, even though management says funding is in place and closing is on track.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 53.83M
- Float Shares
- 53.61M
of shares held by institutions
358 13F filers
Buy/sell ratio 2.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for FUL, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Van TaylorHouse · TX03 | Sell | Mar 25, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 8.18M | ▼ 129.46K |
| Vanguard Group Inc | 6.33M | ▼ 13.89K |
| Vanguard Portfolio Management LLC | 4.02M | ▲ 168.34K |
| Dimensional Fund Advisors LP | 3.20M | ▲ 345.20K |
| State Street Corp | 2.84M | ▼ 20.73K |
| Neuberger Berman Group LLC | 2.65M | ▲ 258.55K |
| Vanguard Capital Management LLC | 2.45M | ▼ 8.87K |
| Mairs & Power Inc | 2.37M | ▼ 66.74K |
| Ancora Advisors LLC | 2.06M | ▲ 798.73K |
| Kayne Anderson Rudnick Investment Management LLC | 1.47M | ▼ 526.84K |
| Geode Capital Management, LLC | 1.40M | ▼ 57.00K |
| Engine Capital Management, LP | 892.95K | ▲ 487.60K |
Held by 438 ETFs
Biggest fund positions in FUL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 26, 27 | Nickless Sarah R. | other | 0 |
| Jan 27, 22 | Nickless Sarah R. | other | 0 |
| Jan 24, 23 | Nickless Sarah R. | other | 0 |
| Jan 27, 26 | Nickless Sarah R. | other | 0 |
| Jan 24, 24 | Nickless Sarah R. | other | 0 |
| Nov 9, 26 | Nickless Sarah R. | other | 0 |
| Jan 26, 25 | Nickless Sarah R. | other | 0 |
| Jan 25, 19 | Nickless Sarah R. | other | 0 |
| Jan 26, 27 | Nickless Sarah R. | other | 0 |
| Jan 27, 26 | Nickless Sarah R. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FUL coverage
Recent articles, reports, and earnings notes.

H.B. Fuller (FUL): Medical Adhesives Drive the Upside
H.B. Fuller is showing improving margins, solid cash generation, and a credible medical adhesives growth story. Leverage and acquisition integration risk keep the stock in Hold territory despite attractive valuation.

H.B. Fuller Company (FUL) slips despite deep earnings beat
H.B. Fuller Company (FUL) slipped after a mixed quarter that paired an adjusted EPS beat with a slight revenue miss. Our deep dive looks beyond the headline, covering margin expansion, segment trends, guidance, leverage, and why investors still see acquisition and execution risk.

H.B. Fuller Company (FUL) slips despite earnings beats
H.B. Fuller Company (FUL) slips 1.1% even after posting earnings beats, as investors weigh the latest results against broader market sentiment.
Want a deeper read on FUL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Here's Why H. B. Fuller (FUL) is a Strong Value Stock
zacks.com · Nov 16
FUL Advances Project Quantum Leap With Seven Site Closures
zacks.com · Nov 13
RPM International (NYSE:RPM) vs. H. B. Fuller (NYSE:FUL) Critical Survey
defenseworld.net · Nov 13
H.B. Fuller Significantly Advances Project Quantum Leap with Announcement of Seven Site Closures
businesswire.com · Nov 11
Ancora Issues Letter to H.B. Fuller's Board of Directors About the Need to Run a Comprehensive Strategic Review of Alternatives
businesswire.com · Oct 27
Best Dividend Kings: October 2026
seekingalpha.com · Oct 26
Why Is H. B. Fuller (FUL) Up 1.8% Since Last Earnings Report?
zacks.com · Oct 23
Why H. B. Fuller (FUL) is a Top Value Stock for the Long-Term
zacks.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice